• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BCRX

    BioCryst Pharmaceuticals Inc.

    Subscribe to $BCRX
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.

    IPO Year: 1994

    Exchange: NASDAQ

    Website: biocryst.com

    Peers

    $APLS
    $IDRA
    $KALV
    $XFOR

    Recent Analyst Ratings for BioCryst Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    4/29/2025$20.00Overweight
    Cantor Fitzgerald
    2/25/2025$15.00Outperform
    Wedbush
    11/20/2023$10.00Overweight
    JP Morgan
    9/18/2023$9.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    8/4/2023$11.00Hold → Buy
    Jefferies
    7/13/2023$10.00Neutral → Buy
    BofA Securities
    2/22/2023$14.00Hold → Buy
    Needham
    11/2/2022$14.00 → $16.00In-line → Outperform
    Evercore ISI
    8/5/2022Outperform → Perform
    Oppenheimer
    8/5/2022$14.00Outperform → In-line
    Evercore ISI
    See more ratings

    BioCryst Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

      —Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome— RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We started 202

      5/5/25 7:00:50 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 48,000 shares of BioCryst common stock. The RSUs were granted as of May 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company

      5/2/25 7:00:30 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Steve Frank to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank direct

      5/1/25 7:00:20 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Present at Upcoming Investor Conferences

      RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 9:00 a.m. ET. Bank of America 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 1:40 p.m. ET. 2025 RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 21, 2025, at 3:05 p.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst's website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioC

      4/30/25 7:00:01 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Report First Quarter 2025 Financial Results on May 5

      RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global b

      4/21/25 7:00:19 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,500 shares of BioCryst common stock. The RSUs were granted as of April 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the comp

      4/4/25 7:00:08 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Present at Upcoming Investor Conference

      RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design t

      4/2/25 4:01:05 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,900 shares of BioCryst common stock. The RSUs were granted as of March 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the com

      3/6/25 7:00:51 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

      —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema targeted by end of year— —Company expects to expand ORLADEYO label to children with HAE aged 2 to 11 using oral gra

      2/24/25 7:00:48 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

      –Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function– –Data will be presented in five posters at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress– RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced positive results from an interim analysis of the ongoing APeX-P clinical trial evaluating an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to

      2/24/25 6:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    BioCryst Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • BioCryst Appoints Steve Frank to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank direct

      5/1/25 7:00:20 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Dr. Donald Fong Chief Medical Officer

      RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company's new chief medical officer, effective immediately. Dr. Fong joins Dr. Helen Thackray, the company's chief research and development officer, and Dr. Bill Sheridan, the company's chief development officer, as physicians on the company's leadership team. "We continue to advance our pipeline of novel therapies to treat diseases with significant unmet needs, including programs in Netherton syndrome and diabetic macular edema that we expect will enter the clinic this year and next year, respectively. Dona

      9/5/24 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

      RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. "I am honored to succeed Bob Ingram. He was a model of effective board leadership for us. Our board is comprised of exceptional people with diverse experience and I am excited to continue working alongside them and the management team to deliver innovative new therapies to patients with rare diseases," said Dr. Hutson. Dr. Hutson was appointed to the board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutica

      3/31/23 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

      RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company's significant pipeline of development candidates. Dr. Ryan Arnold has been appointed as the company's new chief medical officer. Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the company's chief research and development officer, as physicians on the company's leadership team. "Our research and development platform continues to generate exciting opportunities across multiple rare disease targets and Bill's deep knowledge of our portfolio and dedicated focus on our pipelin

      9/14/22 4:01:10 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence

      BOSTON and DURHAM, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence. These moves are designed to strengthen the company's medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales and delivery to delight customers, build repeat business and lead the market in the next phase of drug development transformation. As Chief Operating and Growth Officer, Ms. Howell will

      9/14/22 9:00:00 AM ET
      $BCRX
      $TNDM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
    • BioCryst Appoints Machelle Sanders to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed North Carolina Secretary of Commerce, and accomplished pharmaceutical operations executive, Machelle Sanders, to its board of directors. Ms. Sanders has more than 30 years of pharmaceutical and biotechnology experience with increasing levels of quality assurance and manufacturing operations responsibilities with Biogen, Purdue Pharmaceuticals and AkzoNobel. Most recently she led product operations for Biogen's $8 billion multiple sclerosis franchise and was vice president of manufacturing and general manager for Biogen's 1,200 employee

      2/8/22 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer

      RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Jinky Ang Rosselli as chief data and insights officer. In this new role, Ms. Rosselli will lead a global team to leverage and build the company's data science, analytics and insights infrastructure, helping inform strategic decision making at BioCryst. In her new role, Ms. Rosselli will join the BioCryst leadership team and report directly to Jon Stonehouse, chief executive officer of BioCryst. "Jinky's ability to employ traditional and non-traditional methods to insight gathering, evidence generation and data science has proven to be a critical

      11/1/21 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Dr. Amy McKee to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed regulatory expert and former deputy center director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE), Amy McKee, M.D., to its board of directors. Dr. McKee currently serves as vice president of regulatory consulting services for Parexel, a leading global clinical research organization. Prior to joining Parexel in 2019, Dr. McKee spent more than a decade at the FDA in leadership roles of increasing responsibility. While there, she applied flexible, evidence-based regulatory approaches to assess novel d

      9/20/21 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Dr. Steven Galson to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), and former acting surgeon general, Steven Galson, M.D., MPH to its board of directors. Most recently, Dr. Galson served as the senior vice president, research and development at Amgen. Prior to joining Amgen in 2010, where he also led regulatory affairs, Dr. Galson spent more than 20 years in public service roles across the U.S. Department of Health and Human Services (HHS), Department of Energy (DOE), Environmental Protection

      8/26/21 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Appoints Vincent Milano to Board of Directors

      RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors. Mr. Milano currently serves as chief executive officer of Idera Pharmaceuticals, Inc., and previously served as chairman, president and chief executive officer of ViroPharma, which successfully developed and launched Cinryze for the treatment of HAE in the United States and Europe, prior to its acquisition by Shire in 2014. Prior to joining ViroPharma in 1996, he served as a senior manager at KPMG LLP, an independent registered publ

      7/28/21 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    BioCryst Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      11/7/24 10:52:17 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      11/7/24 10:25:46 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      11/4/24 11:18:36 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      10/17/24 11:52:34 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      2/14/24 4:21:51 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by BioCryst Pharmaceuticals Inc.

      SC 13G - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      2/14/24 9:02:50 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      2/13/24 5:00:45 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      1/24/24 1:06:08 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      2/14/23 4:00:45 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc. (Amendment)

      SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      2/9/23 11:12:40 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    BioCryst Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/31/24 4:25:31 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/29/24 4:16:35 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/22/24 7:24:51 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Milano Vincent bought $93,750 worth of shares (15,000 units at $6.25), increasing direct ownership by 29% to 66,997 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/22/24 7:21:21 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Doyle Anthony bought $202,191 worth of shares (36,300 units at $5.57), increasing direct ownership by 16% to 266,744 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/15/24 7:19:34 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Thackray Helen M. bought $175,800 worth of shares (30,000 units at $5.86), increasing direct ownership by 12% to 272,139 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/15/24 7:17:30 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galson Steven K bought $120,451 worth of shares (21,940 units at $5.49), increasing direct ownership by 74% to 51,551 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/15/24 7:14:54 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barnes Alane P bought $27,650 worth of shares (5,000 units at $5.53), increasing direct ownership by 2% to 300,762 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/15/24 7:11:17 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stonehouse Jon P bought $166,500 worth of shares (30,000 units at $5.55), increasing direct ownership by 3% to 1,127,770 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/15/24 7:08:16 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gayer Charles K bought $164,100 worth of shares (30,000 units at $5.47), increasing direct ownership by 11% to 307,533 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/15/24 7:04:53 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    BioCryst Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on BioCryst Pharma with a new price target

      Cantor Fitzgerald initiated coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $20.00

      4/29/25 8:10:45 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on BioCryst Pharma with a new price target

      Wedbush initiated coverage of BioCryst Pharma with a rating of Outperform and set a new price target of $15.00

      2/25/25 8:02:33 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on BioCryst Pharma with a new price target

      JP Morgan resumed coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $10.00

      11/20/23 7:20:41 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharma upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded BioCryst Pharma from Sector Perform to Outperform and set a new price target of $10.00 from $9.00 previously

      9/18/23 7:31:37 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharma upgraded by Jefferies with a new price target

      Jefferies upgraded BioCryst Pharma from Hold to Buy and set a new price target of $11.00

      8/4/23 8:55:47 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharma upgraded by BofA Securities with a new price target

      BofA Securities upgraded BioCryst Pharma from Neutral to Buy and set a new price target of $10.00

      7/13/23 7:18:31 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharma upgraded by Needham with a new price target

      Needham upgraded BioCryst Pharma from Hold to Buy and set a new price target of $14.00

      2/22/23 7:44:13 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharma upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded BioCryst Pharma from In-line to Outperform and set a new price target of $16.00 from $14.00 previously

      11/2/22 7:07:54 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharma downgraded by Oppenheimer

      Oppenheimer downgraded BioCryst Pharma from Outperform to Perform

      8/5/22 7:45:06 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharma downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded BioCryst Pharma from Outperform to In-line and set a new price target of $14.00

      8/5/22 7:44:44 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    BioCryst Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

      —Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome— RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We started 202

      5/5/25 7:00:50 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Report First Quarter 2025 Financial Results on May 5

      RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global b

      4/21/25 7:00:19 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

      —ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)— —FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 million (previously $515-$535 million)— —GAAP operating loss for full year 2024 was $2.5 million; company achieved $62.9 million non-GAAP operating profit in full year 2024 (not including stock-based compensation), expects to approach positive EPS and positive cash flow in 2H 2025— —Initial clinical data from BCX17725 in Netherton syndrome and avoralstat in diabetic macular edema targeted by end of year— —Company expects to expand ORLADEYO label to children with HAE aged 2 to 11 using oral gra

      2/24/25 7:00:48 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

      RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a gl

      2/10/25 7:00:05 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

      — Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — — BCX17725 for Netherton syndrome advances into the clinic — — Company generates GAAP operating profit of $7.7 million in third quarter ($24.9 million non-GAAP operating profit) — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the third quarter ended September 30, 2024, and p

      11/4/24 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Report Third Quarter 2024 Financial Results on November 4

      RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob

      10/21/24 7:00:23 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

      —Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "The first half of 2024 has been outstanding for BioCryst due to the success we are having in the marketplace with ORLADEYO. As a result, we are in

      8/5/24 7:00:24 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Report Second Quarter 2024 Financial Results on August 5

      RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a

      7/22/24 7:00:09 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

      —Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We are off to a fantastic start to the year with outstanding ORLADEYO revenue growth and our prioritized pipeline programs advancing on schedule. We are focused on co

      5/6/24 7:00:00 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst to Report First Quarter 2024 Financial Results on May 6

      RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global b

      4/22/24 7:00:50 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    BioCryst Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Frank Steven was granted 1,866 shares (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/6/25 4:31:09 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Frank Steven

      3 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      5/6/25 4:18:20 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief R&D Officer Thackray Helen M. covered exercise/tax liability with 7,525 shares, decreasing direct ownership by 2% to 377,318 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      4/2/25 4:18:50 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Milano Vincent was granted 653 shares, increasing direct ownership by 0.86% to 76,737 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      3/4/25 4:18:46 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Gayer Charles K was granted 125,950 shares and covered exercise/tax liability with 2,461 shares, increasing direct ownership by 41% to 423,546 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      12/23/24 4:19:15 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief R&D Officer Thackray Helen M. was granted 125,950 shares and covered exercise/tax liability with 6,096 shares, increasing direct ownership by 45% to 384,843 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      12/23/24 4:15:26 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Doyle Anthony was granted 120,700 shares and covered exercise/tax liability with 2,461 shares, increasing direct ownership by 46% to 377,867 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      12/23/24 4:11:24 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Barnes Alane P covered exercise/tax liability with 2,461 shares and was granted 120,700 shares, increasing direct ownership by 40% to 412,729 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      12/23/24 4:05:25 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President & CEO Stonehouse Jon P was granted 362,100 shares, covered exercise/tax liability with 14,010 shares, gifted 20,000 shares and received a gift of 20,000 shares, increasing direct ownership by 30% to 1,429,109 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      12/23/24 4:01:43 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Gayer Charles K covered exercise/tax liability with 8,251 shares, decreasing direct ownership by 3% to 300,057 units (SEC Form 4)

      4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

      12/17/24 4:22:19 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    BioCryst Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by BioCryst Pharmaceuticals Inc.

      10-Q - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      5/6/25 4:03:08 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      5/5/25 7:11:43 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      5/1/25 7:14:15 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by BioCryst Pharmaceuticals Inc.

      DEFA14A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      4/24/25 4:27:39 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by BioCryst Pharmaceuticals Inc.

      DEF 14A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      4/24/25 4:03:12 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by BioCryst Pharmaceuticals Inc.

      SCHEDULE 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

      4/17/25 9:35:27 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      4/10/25 4:02:05 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      3/11/25 6:26:21 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

      8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      3/4/25 8:01:02 AM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by BioCryst Pharmaceuticals Inc.

      10-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

      2/25/25 4:02:49 PM ET
      $BCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care